Healthcare Industry News: ultrasound
News Release - October 14, 2020
NuVera Medical Announces Positive Results From First-in-human Feasibility Study At 2020 TCT ConferenceAbstract presentation highlights benefit of advanced imaging with novel NuVision™ 4D ICE Catheter
LOS GATOS, Calif., Oct. 14, 2020 -- (Healthcare Sales & Marketing Network) -- NuVera Medical, Inc., a portfolio company of Shifamed LLC focused on enabling a new era in transcatheter cardiac interventions through the advancement of current 4D ICE imaging, today presented positive results from its first-in-human (FIH) feasibility study performed by principal investigator, Dr. Adrian Ebner, Head of the Cardiovascular Department at the Universidad Nacional de Asuncion in Asuncion, Paraguay. Data was highlighted in an abstract presentation by Dr. Azeem Latib, Director of Interventional Cardiology and Structural Heart Interventions at the Montefiore Medical Center in New York, NY as part of the 32nd Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation.
"Initial clinical experience of the NuVision ICE Catheter supports safe and effective use with all primary and secondary safety and performance endpoints met and zero adverse events reported," commented Dr. Latib. "This state-of-the-art 4D ultrasound technology will undoubtedly be the future of procedural guidance across a wide range of electrophysiology and structural heart procedures. I look forward to the benefit this advancement will bring to my practice and for my patients."
One of the first virtually-supported clinical studies performed during the COVID-19 pandemic, the prospective, non-randomized, single-center FIH study investigated the feasibility of the NuVision™ ICE Catheter in visualizing anatomical structures in patients being evaluated for structural heart procedures such as atrial septal defect (ASD) or patent foremen ovale (PFO) closure, left atrial appendage (LAA) closure, and mitral or tricuspid valve repairs.
"The NuVision ICE Catheter provided me a completely new perspective in imaging of complex intracardiac structures and I could easily visualize the structures for catheter guidance," stated Dr. Ebner. "All procedures were performed under conscious sedation and did not require intubation, which reduced overall length of stay, exposure to fluoroscopy and staffing demands. I believe NuVera's novel solution has the potential to be an alternative to TEE for procedural guidance in structural heart interventions."
"We are very pleased with the results of the initial patient experience and thank the outstanding clinical team for making this virtually-supported study a success," said Todor Jeliaskov, President CEO of NuVera Medical. "We are happy to see the NuVision ICE Catheter simplified complex procedures for greater physician and patient benefit and look forward to building on this clinical experience as we prepare to bring our advanced imaging technology to market."
About NuVera Medical, Inc.
NuVera Medical is a privately held medical device company formed by Shifamed LLC, a Silicon Valley based medical innovation hub. The company is developing the NuVera ICE Catheter to enable a new era in transcatheter cardiac interventions through the advancement of 4D intracardiac echocardiography (4D ICE). The NuVera ICE Catheter is currently in the clinical, pre-commercial stage and not available for sale. To learn more about NuVera Medical, please visit www.nuveramedical.com.
About Shifamed, LLC
Founded by serial entrepreneur Amr Salahieh, Shifamed LLC is a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com.
Source: NuVera Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.